Renishaw plc stock (GB0007365546): Precision engineering leader with global metrology reach

Renishaw plc maintains its position as a global leader in precision measurement and healthcare technologies. The company, listed on the London Stock Exchange, reported steady performance in its core segments during the fiscal year ended June 2024, with revenue of £688.6 million, according to Renishaw investor relations as of September 2024. This reflects resilience in metrology and additive manufacturing amid supply chain challenges.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Renishaw plc: core business model

Renishaw plc develops and sells advanced precision measurement and healthcare products worldwide. Founded in 1973, the company pioneered the touch-trigger probe, revolutionizing coordinate measuring machines (CMMs). Today, its metrology division provides gauging systems, encoders, and calibration tools essential for manufacturing accuracy. Healthcare offerings include neurosurgical robots and Raman spectroscopy for diagnostics. With over 5,000 employees across 36 countries, Renishaw emphasizes R&D, investing 16% of revenue in innovation as of fiscal 2024, per Renishaw annual report June 2024.

The business model relies on a mix of proprietary technology and application engineering. Renishaw serves high-precision industries where sub-micron accuracy is critical, generating recurring revenue from consumables like styli and software updates. Its additive manufacturing arm, Renishaw Americas in North Carolina, supports US clients directly, enhancing relevance for American investors tracking industrial tech exposure.

Main revenue and product drivers for Renishaw plc

Metrology accounts for approximately 60% of revenue, driven by products like the REVO-2 system for 5-axis CMMs and QUANTAM interferometry for machine tool calibration. In fiscal 2024 (ended June 30, 2024), this segment grew 5% year-over-year to £411 million, fueled by demand in aerospace and automotive sectors, according to company filings. Additive manufacturing contributed £137 million, with metal 3D printers like QuantAM gaining traction for titanium parts in medical implants.

Healthcare products, including the Neuromate robot used in over 200,000 brain surgeries globally, represent a high-margin growth area. Spectroscopy tools for pharmaceutical analysis add diversification. US revenue exposure exceeds 25%, with key clients like Boeing and GE Healthcare underscoring Renishaw's role in the American manufacturing ecosystem, as noted in investor presentations from 2024.

Industry trends and competitive position

The precision metrology market is projected to grow at 6.5% CAGR through 2030, per Statista data published 2025, driven by Industry 4.0 and automation. Renishaw competes with Hexagon AB and Zeiss but leads in probe technology patents, holding over 5,000 worldwide. Its vertical integration—from sensors to software—provides a competitive edge in quality control for electric vehicle battery production and semiconductor fabs.

In additive manufacturing, Renishaw's focus on process monitoring differentiates it from EOS and SLM Solutions. The company's US presence, including a Hoffman Estates, Illinois facility, positions it well for reshoring trends under US industrial policy.

Why Renishaw plc matters for US investors

Renishaw offers US investors indirect exposure to UK engineering excellence via its LSE ADR availability and strong transatlantic ties. With 27% of sales from North America in fiscal 2024, the company benefits from US aerospace recovery post-Boeing supply issues and medical device demand amid aging demographics. Its tech aligns with CHIPS Act investments in precision tooling for chip manufacturing.

Read more

Conclusion

Renishaw plc stands as a cornerstone in precision technologies, with robust fundamentals in metrology and growing additive manufacturing capabilities. Fiscal 2024 results highlight operational strength despite macroeconomic headwinds, while US market exposure offers diversified appeal. Investors monitoring industrial innovation will note its strategic positioning amid global manufacturing shifts.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.